Irritable Bowel Syndrome (IBS) Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs. As of October 2014, there were four products indicated for IBS in the 7MM. These include the constipation-predominant IBS (IBS-C) therapies, Sucampo/Takeda/Abbott's Amitiza (lubiprostone) and Ironwood/Actavis/Almirall/Astellas' Linzess (linaclotide), and the diarrheapredominant IBS (IBS-D) therapies, Prometheus' Lotronex (alosetron) and Astellas' Irribow (ramosetron). Antidepressants and antibiotics (mainly Salix/Alfa Wassermann/Norgine/BamaGeve's Xifaxan [rifaximin]), are also commonly used off-label to treat IBS. GlobalData anticipates that four new therapies have the potential to enter the IBS market during the 20132023 forecast period. This includes Furiex's (Actavis') eluxadoline and Menarini's ibodutant for IBS-D, and Synergy's plecanatide and AstraZeneca/Ardelyx's tenapanor for IBS-C. In addition, Xifaxan is in development for IBS-D, and has the potential to gain a label expansion for this indication during the forecast period. Read Complete Report with TOC: http://www.radiantinsights.com/research/pharmapointirritable-bowel-syndrome-global-drug-forecast-and-market-analysis-to-2023 Highlights Key Questions Answered - What do physicians think about Ironwood/Actavis/Almirall/Astellas' Linzess and what will be the impact in the IBS market following its launch in 2012 in the US and 2013 in the 5EU region? - What will be the uptake of Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan following its anticipated label-expansion for IBS-D and how will it impact the treatment paradigm for IBS? - What is the significance of late-phase pipeline products for IBS and how will their launch shape the future treatment landscape in IBS? - What are the significant unmet needs in the IBS market? - What are the remaining opportunities in the IBS market? Key Findings - The IBS market value will be driven by the increasing uptake of Ironwood/Actavis/Almirall/Astellas' Linzess and its expected launch in all the major European
markets and Japan, the anticipated label expansion of Salix/Alfa Wassermann/Norgine/BamaGeve's Xifaxan for IBS-D, the potential introduction of four pipeline drugs for the treatment of IBS, and the increasing prevalent cases of IBS. - The main corporate strategy trend in the IBS market is for companies to enter into partnerships for the successful co-development and co-marketing of products in the different global regions. - The most pressing unmet need in the IBS market is for the development of drugs with improved efficacy. Scope - Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. - Annualized IBS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the IBS market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs. - Analysis of the current and future market competition in the global IBS market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare Reasons To Buy - Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global IBS market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IBS market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global IBS market from 2013-2023. - Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Table Of Content: Table of Contents 8
1.1 List of Tables 14 1.2 List of Figures 18 2 Introduction 20 2.1 Catalyst 20 2.2 Related Reports 20 3 Disease Overview 21 3.1 Etiology and Pathophysiology 21 3.1.1 Etiology 21 3.1.2 Pathophysiology 22 3.2 Classification 22 3.3 Symptoms 23 3.4 Prognosis 23 3.5 Quality of Life 24 To Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/pharmapoint-irritable-bowel-syndrome-globaldrug-forecast-and-market-analysis-to-2023#tabs-4 4 Epidemiology 25 4.1 Disease Background 25 4.2 Risk Factors and Comorbidities 26 4.3 Global Trends 27 4.3.1 US 29 4.3.2 5EU 31 4.3.3 Japan 31 4.4 Forecast Methodology 32 4.4.1 Sources Used 32 4.4.2 Sources Not Used 38 4.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of IBS 39 4.4.4 Forecast Assumptions and Methods - IBS Subtype Segmentations 42 4.5 Epidemiological Forecast for IBS (2013-2023) 44 4.5.1 Total Prevalent Cases of IBS 44 4.5.2 Age-Specific Total Prevalent Cases of IBS 46 4.5.3 Sex-Specific Total Prevalent Cases of IBS 48 4.5.4 Age-Standardized Total Prevalence of IBS 50 4.5.5 Total Prevalent Cases of IBS by Clinical Subtype 51 4.6 Discussion 53 4.6.1 Epidemiological Forecast Insight 53 4.6.2 Limitations of the Analysis 54 4.6.3 Strengths of the Analysis 56 5 Disease Management 57 5.1 Diagnosis and Treatment Overview 57
5.1.1 Diagnosis 57 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 59 5.1.3 Clinical Practice 62 5.2 US 64 5.3 France 66 5.4 Germany 68 5.5 Italy 70 5.6 Spain 72 5.7 UK 74 5.8 Japan 76 6 Competitive Assessment 78 6.1 Overview 78 6.2 Product Profiles - Major Brands, IBS-C 79 6.2.1 Amitiza (lubiprostone) 79 6.2.2 Linzess (linaclotide) 85 6.3 Product Profiles - Major Brands, IBS-D 93 6.3.1 Lotronex (alosetron) 93 6.3.2 Irribow (ramosetron) 98 6.4 Product Profiles - Major Brands, Other 103 6.4.1 Antidepressants 103 6.5 Other Therapeutic Classes 108 To Get More Details @ http://www.radiantinsights.com/research/pharmapoint-irritablebowel-syndrome-global-drug-forecast-and-market-analysis-to-2023 7 Unmet Need and Opportunity 110 7.1 Overview 110 7.2 More Effective Pharmacotherapies 111 7.2.1 Unmet Need 111 7.2.2 Gap Analysis 112 7.2.3 Opportunity 113 7.3 Therapies for the IBS-D Subtype 113 7.3.1 Unmet Need 113 7.3.2 Gap Analysis 114 7.3.3 Opportunity 114 7.4 Therapies for the IBS-M Subtype 114 7.4.1 Unmet Need 114 7.4.2 Gap Analysis 115 7.4.3 Opportunity 115 7.5 Therapies to Address Abdominal Pain and Bloating Symptoms 115 7.5.1 Unmet Need 115 7.5.2 Gap Analysis 116 7.5.3 Opportunity 116 7.6 Improved Diagnosis Rate for IBS 117
7.6.1 Unmet Need 117 7.6.2 Gap Analysis 117 7.6.3 Opportunity 117 8 Pipeline Assessment 119 8.1 Overview 119 8.2 Clinical Trial Mapping 119 8.2.1 Clinical Trials by Therapy Type 119 8.3 Promising Drugs in Clinical Development 120 8.4 Product Profiles - Late-Stage Pipeline, IBS-D 123 8.4.1 Eluxadoline 123 8.4.2 Ibodutant (MEN-15596) 130 8.4.3 Xifaxan (rifaximin) 136 8.5 Product Profiles - Late-Stage Pipeline, IBS-C 145 8.5.1 Plecanatide 145 8.5.2 Tenapanor (AZD1722, RDX5791) 151 8.6 Other Drugs in Development for IBS 156 To Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/pharmapoint-irritable-bowel-syndrome-globaldrug-forecast-and-market-analysis-to-2023#tabs-4 9 Current and Future Players 157 9.1 Overview 157 9.2 Trends in Corporate Strategy 159 9.3 Company Profiles 160 9.3.1 Actavis 160 9.3.2 Astellas 162 9.3.3 Almirall 165 9.3.4 Ironwood 166 9.3.5 Takeda 169 9.3.6 Sucampo 171 9.3.7 Prometheus 173 9.3.8 Salix 175 9.3.9 Menarini 177 9.3.10 Synergy 179 9.3.11 AstraZeneca 181 10 Market Outlook 183 10.1 Global Markets 183 10.1.1 Forecast 183 10.1.2 Drivers and Barriers - Global Issues 187 10.2 US 188
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com